Clinical significance of the antibody against oxidized low-density lipoprotein in acute myocardial infarction

Cardiology. 2002;98(1-2):13-7. doi: 10.1159/000064672.

Abstract

To establish the clinical significance of the antibody against oxidized low-density lipoprotein (anti-Ox-LDL) titer in patients with acute myocardial infarction (AMI), we measured the anti-Ox-LDL titer in 39 patients with AMI and 25 controls. In all AMI patients, the anti-Ox-LDL titer on admission was higher (p < 0.05) than the value in the controls. One month after admission, the titer decreased significantly (p < 0.001) reaching control levels. In patients who underwent thrombolytic therapy, the anti-Ox-LDL titer on admission was identical in patients with occluded infarct-related arteries (IRA) and patients with patent IRA during emergency coronary angiography. In patients who did not undergo thrombolytic therapy, the anti-Ox-LDL titer on admission was higher in patients with occluded IRA than in patients with patent IRA. An increased anti-Ox-LDL titer may be a risk factor for the onset of AMI. Spontaneous recanalization of the IRA may be associated with increased anti-Ox-LDL titers, while thrombolysis-induced recanalization may be independent of it.

Publication types

  • Clinical Trial
  • Comparative Study
  • Evaluation Study
  • Randomized Controlled Trial

MeSH terms

  • Antibodies / therapeutic use*
  • Arteries / pathology
  • Biomarkers / blood
  • Cholesterol, LDL / drug effects
  • Cholesterol, LDL / metabolism
  • Coronary Angiography
  • Coronary Vessels / pathology
  • Female
  • Humans
  • Japan
  • Lipoproteins, LDL / immunology*
  • Male
  • Middle Aged
  • Myocardial Infarction / drug therapy*
  • Myocardial Infarction / metabolism
  • Patient Admission
  • Prospective Studies
  • Treatment Outcome
  • Vascular Patency / drug effects
  • Vascular Patency / physiology

Substances

  • Antibodies
  • Biomarkers
  • Cholesterol, LDL
  • Lipoproteins, LDL
  • oxidized low density lipoprotein